Valuation: Thalia Therapeutics Plc

Market Cap 10.21M 13.63M 12.19M 11.28M 19.11M 1.3B 19.42M 136M 53.68M 678M 51.16M 50.07M 2.15B P/E 2024
-1.69x
P/E 2025 -3.09x
Enterprise Value 9.13M 12.19M 10.9M 10.08M 17.09M 1.16B 17.37M 121M 48M 607M 45.75M 44.77M 1.92B EV / Sales 2024
198,657,512x
EV / Sales 2025 452,941,079x
Free-Float
41.35%
Yield 2024 *
-
Yield 2025 -
1 day+4.35%
1 week-4.00%
Current month-4.00%
3 months-14.29%
6 months+4.35%
Current year+14.29%
1 week 0.55
Extreme 0.55
0.65
1 month 0.55
Extreme 0.55
0.65
Current year 0.4
Extreme 0.4
0.95
1 year 0.4
Extreme 0.4
0.95
3 years 0.35
Extreme 0.35
1.5
5 years 0.35
Extreme 0.35
8.69
10 years 0.35
Extreme 0.35
35.7
Manager TitleAgeSince
Chief Executive Officer 66 2026-02-23
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 56 2025-05-26
Director TitleAgeSince
Director/Board Member 48 2020-07-13
Chairman 59 2023-07-31
Director/Board Member 81 2024-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
11/28/24 Free

Founder

6,000,000 1.5198%
11/28/24 Free

Director

3,000,000 0.7599%
11/28/24 Free

Chairman

3,000,000 0.7599%
Change 5-day change 1-year change 3-year change Capi.($)
+4.35%-4.00%-7.69%-29.41% 13.63M
+0.88%-0.34%+40.64%+73.05% 65.28B
-0.15%-0.15%+9.63%+77.21% 54.57B
-0.35%+1.02%+9.13%+100.70% 53.59B
-2.06%+2.90%+24.07%+48.36% 45.03B
-1.79%+0.19%+19.32%+123.62% 42.17B
-1.65%+0.96%+237.56%+823.66% 39.42B
-2.26%-4.14%+15.38%+45.53% 32.71B
-2.70%-10.77%+19.80%-6.47% 24.01B
+0.46%+14.26%+58.98%+48.13% 26.5B
Average -0.53%+1.36%+42.68%+130.44% 38.33B
Weighted average by Cap. -0.86%+2.27%+45.58%+148.30%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.92 0.01 0.1 0.04 0.48 0.04 0.04 1.53 0.01 0.01 0.01 0.01 0.01 0.92 0.01 0.1 0.04 0.48 0.04 0.04 1.53
Net income -1.06M -1.41M -1.26M -1.17M -1.98M -134M -2.01M -14.07M -5.57M -70.33M -5.3M -5.19M -223M -1.21M -1.61M -1.44M -1.33M -2.26M -153M -2.29M -16.02M -6.33M -80.05M -6.04M -5.91M -253M
Net Debt -626K -836K -747K -691K -1.17M -79.51M -1.19M -8.32M -3.29M -41.59M -3.14M -3.07M -132M -1.08M -1.44M -1.29M -1.19M -2.02M -137M -2.05M -14.34M -5.67M -71.7M -5.41M -5.29M -227M
Projected Income Statement - Annual - Thalia Therapeutics Plc
Logo Thalia Therapeutics Plc
Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.
Employees
3
Date Price Change Volume
26-10-27 GBX 0.6000 +4.35% 6,851
26-10-26 GBX 0.5750 0.00% 536,216
26-10-23 GBX 0.5750 -4.17% 157,698
26-10-22 GBX 0.6000 0.00% 18,295
26-10-21 GBX 0.6000 -4.00% 431,106
  1. Stock Market
  2. Stocks
  3. THAT Stock